OncRef

Clinical Trial: NCT03001882

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2024-05-20

Study Overview

Brief Summary

The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).

Official Title

An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Biological: Nivolumab
  • Biological: Ipilimumab

Other Study ID Numbers

  • CA209-592
  • 2018-000462-11
  • 2018

Start Date (Actual)

2017-03-29

Primary Completion Date (Actual)

2022-02-17

Study Completion Date (Actual)

2023-04-24

Enrollment (Actual)

230

Study Type

Interventional

Phase

Phase 2